• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 17, 2023 at 09:33: PM
via Lyndra Therapeutics is laying off roughly 23% of its staff, two months after the company swapped out longtime CEO Patricia Hurter, Ph.D., and as a pivotal trial for a long-acting, oral schizophrenia drug nears an interim readout.

article source
 




Top Bottom
Back
Quote